BackNewAmsterdam Pharma Company NV Overview

NewAmsterdam Pharma Company NV Current Cash

Track NewAmsterdam Pharma Company NV's current cash ($420M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$424.15M
↓ 24.78% YoYΔ $-139.71M vs prior year quarter

Peer trimmed avg / median

Loading

NewAmsterdam Pharma Company NV Current Cash History

Loading

NewAmsterdam Pharma Company NV vs. peers: Current Cash Comparison

Loading

NewAmsterdam Pharma Company NV Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NewAmsterdam Pharma Company NV (NAMS) FAQ

NewAmsterdam Pharma Company NV (NAMS) currently reports a current cash of $420M as of June 2026. That compares with $560M in the prior-year period — down 24.8% year over year. Use the charts on this page to explore NewAmsterdam Pharma Company NV's current cash history and peer comparisons.

NewAmsterdam Pharma Company NV's current cash decreased from $560M to $420M — a 24.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NewAmsterdam Pharma Company NV reported $420M in current cash as of June 2026. That compares with $560M in the prior-year period — down 24.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $420M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NewAmsterdam Pharma Company NV, and consider following NAMS for alerts when major investors trade the stock.